BTK and hematopoietic and lymphoid cell neoplasm: Ibrutinib is intended for selected hematologic cancers; it is a first-in-class, potent, orally administered drug, that covalently binds to Bruton’s tyrosine kinase (BTK) and inhibits B-cell antigen receptor signalling downstream of BTK [13].